Omeros Corporation

Omeros Corporation is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Omeros Corporation could be a weak company given it's low Piotroski F-score. Omeros Corporation price momentum is very positive. Omeros Corporation is not a good value stock. Omeros Corporation is not a good growth stock. Omeros Corporation is not very popular among insiders. Omeros Corporation is a mediocre stock to choose.
Log in to see more information.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and...
OMER Fundamental Data by TradingView

News

Omeros Corporation's (NASDAQ:OMER) 14% loss last week hit both individual investors who own 52% as well as institutions
Omeros Corporation's (NASDAQ:OMER) 14% loss last week hit both individual investors who own 52% as well as institutions

Simply Wall St Key Insights The considerable ownership by retail investors in Omeros indicates that they collectively have a greater...\n more…

Omeros Co. (NASDAQ:OMER) Shares Acquired by Vanguard Group Inc.
Omeros Co. (NASDAQ:OMER) Shares Acquired by Vanguard Group Inc.

Ticker Report Vanguard Group Inc. grew its stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 2.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities...\n more…

Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com
Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com

Ticker Report Omeros (NASDAQ:OMER - Get Free Report) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday...\n more…

OMER Stock Earnings: Omeros Misses EPS for Q2 2024
OMER Stock Earnings: Omeros Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nOMER stock results show that Omeros missed analyst estimates for earnings per share the second quarter of 2024.\nThe post OMER Stock...\n more…

Omeros Corporation Reports Second Quarter 2024 Financial Results
Omeros Corporation Reports Second Quarter 2024 Financial Results

Business Wire Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and...\n more…

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Business Wire Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes. Omeros...\n more…